26 June 2018
Roche announced on Monday, June 25 that the Phase III IMpower133 study evaluating its anti-programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor (CPI) Tecentriq (atezolizumab) with carboplatin + etoposide (CE), the...
25 June 2018
The development of stem-cell based therapies has been slow even though there are many theoretical applications and benefits associated with these therapies. The challenges of translating potential drugs from clinical...
20 June 2018
On June 12, AstraZeneca and Eli Lilly terminated their two Phase III clinical trials of oral amyloid targeting β-secretase (BACE) inhibitor lanabecestat in Alzheimer’s disease (AD). The partners made the...
22 May 2018
PD-L1 has long been dismissed as a viable biomarker in advanced bladder cancer, given that numerous late-stage clinical trials of PD-1/L1 inhibitors in the disease have reported clinical benefit even...
8 May 2018
The FDA has granted priority review for Merck’s Keytruda (pembrolizumab) + Alimta (pemetrexed injection) + platinum-based chemotherapy combination as a first-line treatment for patients with metastatic non-squamous, non-small cell lung...
30 April 2018
Endometriosis is a gynaecological disorder characterised by growth of endometrial tissue (tissue lining the uterus) in unusual locations, such as the ovaries. It can be extremely painful, and is a...
26 April 2018
Within the GlobalData Pharma Intelligence Center, there are profiles of many drug candidates that focus on the prevention and treatment of colorectal cancer.
24 April 2018
Phase IIa clinical trial immunogenicity and efficacy results of potential Plasmodium falciparum malaria vaccine R21 mixed with adjuvant Matrix M (MM), were presented at the 2018 European Congress of Clinical...
23 April 2018
Anti-PD-(L)1/CTLA-4 checkpoint inhibitors (CPIs) have revolutionized the standard of care treatment paradigm in a variety of cancers.
19 April 2018
Treatment of KRAS-driven cancers is among one of the highest unmet needs in the oncology space.